RedHill Biopharma Ltd. RDHL
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -97.93% | -96.44% | -48.57% | 55.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -97.93% | -96.44% | -48.57% | 55.30% |
| Cost of Revenue | -- | -- | -- | -- | -53.55% |
| Gross Profit | -- | -94.43% | -90.50% | -90.50% | 75.10% |
| SG&A Expenses | 285.31% | 47.96% | -44.44% | 30.98% | 66.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 501.39% | 27.56% | -43.18% | -329.74% | -119.93% |
| Operating Income | -144.79% | 13.00% | 47.60% | 115.83% | 80.19% |
| Income Before Tax | -1,215.20% | -1,091.52% | -915.28% | 105.03% | 100.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,215.20% | -1,091.52% | -915.28% | 105.03% | 100.71% |
| Earnings from Discontinued Operations | 68.20% | -31.80% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.48% | 41.78% | 50.01% | 65.02% | 69.14% |
| EBIT | -144.79% | 13.00% | 47.60% | 115.83% | 80.19% |
| EBITDA | -112.15% | 17.47% | 49.43% | 125.15% | 71.55% |
| EPS Basic | 46.08% | 29.93% | 31.68% | 93.67% | 94.64% |
| Normalized Basic EPS | -- | -202.87% | -656.87% | -82.68% | 107.16% |
| EPS Diluted | 46.08% | 29.93% | 31.68% | 93.67% | 94.64% |
| Normalized Diluted EPS | -- | -202.87% | -656.87% | -82.68% | 107.16% |
| Average Basic Shares Outstanding | -47.80% | -8.53% | 41.01% | 26.50% | 101.62% |
| Average Diluted Shares Outstanding | 150.00% | 100.00% | 50.00% | 33.33% | 100.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |